Last reviewed · How we verify
CYD-TDV Dengue Vaccine
At a glance
| Generic name | CYD-TDV Dengue Vaccine |
|---|---|
| Also known as | Dengvaxia® |
| Sponsor | Sanofi Pasteur, a Sanofi Company |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Cohort Event Monitoring for Dengvaxia®, CYD-TDV Dengue Vaccine
- Observational Study to Evaluate the Safety of CYD Tetravalent Dengue Vaccine (CYD-TDV) in Pregnant Women and Their Offsprings Inadvertently Exposed During Pregnancy
- Dengue Effectiveness Study in the Philippines
- Assessing the Effectiveness of Sanofi Pasteur's Dengue Vaccine (Dengvaxia) Against Hospitalization and Symptomatic Infection in the State of Parana - Brazil
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CYD-TDV Dengue Vaccine CI brief — competitive landscape report
- CYD-TDV Dengue Vaccine updates RSS · CI watch RSS
- Sanofi Pasteur, a Sanofi Company portfolio CI